Hipro Biotechnology Co., Ltd., founded in 2006, is a high-tech enterprise specializing in the R&D, manufacturing, and commercialization of point-of-care (POCT) and in-vitro diagnostic (IVD) solutions. Headquartered in Hebei, China, Hipro operates GMP-standardized manufacturing facilities and advanced automated production lines, with R&D centers in Silicon Valley and Nanjing, and a dedicated microfluidic chip industrial base in Taizhou.
Hipro has developed multiple core technology platforms, including automated immunoassay, microfluidics, single-molecule diagnostics, fluorescence immunoassay, and digital health platforms. The product portfolio covers 75+ diagnostic parameters across biochemistry, immunoassay, nephelometry, fluorescence, and turbidimetry.
With 179 patents, extensive regulatory approvals (NMPA, CE, FDA listings), and products used in 16,000+ medical institutions across 100+ countries, Hipro is a globally recognized IVD company.
